Price movement over the last 24 hours
ADMA Biologics Inc vs Bandwidth Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Bandwidth Inc trades at $69 (market cap $1.94B). The key difference: ADMA Biologics Inc and Bandwidth Inc are close in size by market cap, and Bandwidth Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | BAND | |
|---|---|---|
Market Cap | $2.13B | $1.94B |
Sector | Health | Technology |
52-Week High | $20.38 | $73.19 |
52-Week Low | $7.60 | $12.82 |
Enterprise Value | $2.20B | $2.32B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Bandwidth (BAND) trades at $60.67, down 1.51% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 EPS of $0.38, beating expectations, but maintains negative net income margins. Recent news highlights the launch of the AI-driven Bandwidth Build platform and a $275 million convertible notes offering, fueling growth optimism in cloud communications.
The outlook is mixed: strong analyst buy consensus (75%) and AI expansion offer upside, but profitability concerns and high valuation multiples pose risks. Revenue growth is projected to improve, yet negative ROE and net income require monitoring. The stock's momentum depends on execution of AI initiatives and path to sustained profitability.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →